Trials / Completed
CompletedNCT00940563
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
STI571 (Imatinib) in KIT-expressing Gastrointestinal Stromal Tumors (GIST): a Prospective, Open-label, Multicenter Study on Best Clinical Use in the Advanced Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, multicenter study of imatinib (400mg/die p.o.)in patients with advanced gastrointestinal stromal tumors. Patients will be treated for up to 12 months. Data regarding its best clinical use in terms of tumor response, survival, tolerability and safety profile will be prospectively collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2004-08-01
- First posted
- 2009-07-16
- Last updated
- 2011-07-01
Locations
26 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00940563. Inclusion in this directory is not an endorsement.